Suppr超能文献

减轻肠道微生物群介导的脓毒症小鼠的炎症反应。

Attenuates Inflammation in Septic Mice Mediated by Gut Microbiota.

作者信息

Han Fu, Wu Gaofeng, Zhang Yijie, Zheng Haotian, Han Shichao, Li Xiaoqiang, Cai Weixia, Liu Jiaqi, Zhang Wanfu, Zhang Xiaowei, Hu Dahai

机构信息

Department of Burns and Cutaneous Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.

Key Laboratory of Tissue Repair and Regeneration of PLA and Beijing Key Research Laboratory of Skin Injury, Repair and Regeneration, First Hospital Affiliated to General Hospital of PLA, Beijing, China.

出版信息

Front Microbiol. 2020 Dec 15;11:598010. doi: 10.3389/fmicb.2020.598010. eCollection 2020.

Abstract

Sepsis is a life-threatening organ dysfunction condition caused by a dysregulated host response to infection and lack of effective treatment method. Supplementation of probiotics has emerged as a potential biotherapy for inflammatory diseases in recent years, but its role in protecting viscera against the damage caused by sepsis and the underlying mechanism is poorly understood. 19 is one of the most well-studied probiotics, which is selected in this study among seven strains isolated from homemade yogurt due to its optimal ability of suppressing the inflammation response . It showed significant decrease in the expression of TNF-α, IL-1β, and IL-6 in the co-culture of 19 and LPS-treated mouse macrophage. The effect of 19 in mice and the response of mice gut microbiota were subsequently investigated. In LPS-induced septic mouse model, 19 was highly resistant to LPS and exhibited significantly decreased expressions of inflammatory factors compared to LPS-treated mice. A MiSeq-based 16S rDNA sequence analysis revealed that the decrease of gut microbial diversity in mice intraperitoneally injected with 1 mg/ml LPS were mitigated by the administration of 19. significantly decreased during the development of sepsis and rose again after supplement strain 19, while showed the opposite trend, which demonstrated these two genera were the key bacteria that may function in the mice gut microbiota for alleviation of LPS-induced inflammation reaction. To conclude, 19 may be a potential candidate for novel biotherapeutic interventions against inflammation caused by sepsis.

摘要

脓毒症是一种由宿主对感染的失调反应和缺乏有效治疗方法引起的危及生命的器官功能障碍病症。近年来,补充益生菌已成为治疗炎症性疾病的一种潜在生物疗法,但其在保护内脏免受脓毒症所致损伤方面的作用及潜在机制尚不清楚。19是研究最深入的益生菌之一,在本研究中,从自制酸奶中分离出的7株菌株中选择了它,因为它具有最佳的抑制炎症反应能力。在19与脂多糖(LPS)处理的小鼠巨噬细胞共培养中,它显示肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)和白细胞介素-6(IL-6)的表达显著降低。随后研究了19在小鼠体内的作用以及小鼠肠道微生物群的反应。在LPS诱导的脓毒症小鼠模型中,19对LPS具有高度抗性,与LPS处理的小鼠相比,炎症因子的表达显著降低。基于MiSeq的16S核糖体DNA(rDNA)序列分析表明,腹腔注射1 mg/ml LPS的小鼠肠道微生物多样性的降低通过给予19得到缓解。在脓毒症发展过程中显著降低,在补充菌株19后再次上升,而呈现相反趋势,这表明这两个属是可能在小鼠肠道微生物群中发挥作用以减轻LPS诱导的炎症反应的关键细菌。总之,19可能是针对脓毒症引起的炎症进行新型生物治疗干预的潜在候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b132/7769777/be8807311716/fmicb-11-598010-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验